Transplant International

Cover image for Vol. 29 Issue 8

Edited By: Thomas Wekerle and Rainer Oberbauer

Impact Factor: 2.835

ISI Journal Citation Reports © Ranking: 2015: 12/25 (Transplantation); 40/199 (Surgery)

Online ISSN: 1432-2277

Featured

  • New classification of donation after circulatory death donors definitions and terminology

    New classification of donation after circulatory death donors definitions and terminology

    Uncontrolled DCD process. No flow: Kidney ≤30 min; Liver ≤ 15 minCPR duration: ≥30 minNo-touch period: 2 min to 20 minTotal WIT: 120 min to 150 min

  • Vascularized composite allotransplantation: current standards and novel approaches to prevent acute rejection and chronic allograft deterioration

    Vascularized composite allotransplantation: current standards and novel approaches to prevent acute rejection and chronic allograft deterioration

    Approaches that may improve outcomes and decrease complications after vascularized composite allotransplantation (VCA).

  • Dynamic changes of B-cell compartments in kidney transplantation: lack of transitional B cells is associated with allograft rejection

    Dynamic changes of B‐cell compartments in kidney transplantation: lack of transitional B cells is associated with allograft rejection

    Gating strategy for the determination of human peripheral blood B lymphocyte subpopulations. (a) Definition of B cells via distribution profiles of SS/FS, CD45+, and CD19+. (b) Determination of mature naive cells as IgM+IgD+CD27− B cells. (c) Memory cells are defined by the expression of CD27+ and divided into IgM−CD27+ or IgM−CD21+ switched memory B cells and IgM+CD27+ or IgM+CD21+ nonswitched B cells. (d) Transitional B cells represent the CD24highCD38high subset with same corresponding population of IgMhighCD38high cells; plasmablasts are IgM−CD38high B cells or CD24−CD38high B cells.

  • Complement inhibition as potential new therapy for antibody-mediated rejection

    Complement inhibition as potential new therapy for antibody-mediated rejection

    Schematic illustration of classical complement activation and therapeutic strategies targeting complement. In a first step of the classical cascade, antibodies bound to HLA expressed on donor endothelial cells interact with C1q and stabilize the formation of the C1 complex (Ca2+ dependent). Active C1 subunit C1s cleaves factor C4 into C4a and C4b, the latter providing a binding site for C2 facilitating its cleavage by C1s into C2a and C2b. Under the control of complement-regulatory proteins and Factor I, surface-bound C4b is degraded to C4d. Capillary C4d staining has proven to be a useful diagnostic marker. If strong activation overwhelms these control mechanisms, surface-bound C4b2a becomes a stable, active C3 convertase that cleaves C3 into the anaphylatoxin C3a and C3b which again covalently binds to the surface. The combination of C4b2a with C3b forms the active C5 convertase (C4b2a3b) that can now cleave C5 into the anaphylatoxin C5a and C5b. C5b is responsible for the assembly of the membrane attack complex (MAC) which is inserted in the cell membrane. By stably binding to C5 in a 0.5:1 molar ratio of antibody to C5, eculizumab hinders its cleavage.

  • Clinical consequences of circulating CD28-negative T cells for solid organ transplantation

    Clinical consequences of circulating CD28-negative T cells for solid organ transplantation

    CD28-positive (CD28pos) memory T cells may become CD28 negative (CD28neg) under the influence of repetitive cell proliferation and cytomegalovirus (CMV) infection, which is further promoted by an inflammatory milieu and tumor necrosis factor-alpha (TNF-alpha). The defining characteristics of the CD4 and CD8 CD28neg T cells are shown on the right side. The CD8 CD28neg T cells contain suppressor cells (Tsup). NKR: natural killer receptor.

  • Impact of de novo donor-specific anti-HLA antibodies on grafts outcomes in simultaneous pancreas–kidney transplantation

    Impact of de novo donor-specific anti-HLA antibodies on grafts outcomes in simultaneous pancreas–kidney transplantation

    Death-censored pancreas graft survival in patients with de novo donor-specific anti-HLA antibodies (DSA+, n = 22) and those without (DSA−, n = 128).

  • Eight-year results of the Spiesser study, a randomized trial comparing de novo sirolimus and cyclosporine in renal transplantation

    Eight-year results of the Spiesser study, a randomized trial comparing de novo sirolimus and cyclosporine in renal transplantation

    Patient, death-censored, and graft survival were similar in sirolimus and cyclosporine groups (ITT analysis). Estimated patient survival (a), death-censored graft survival (b), and graft survival (c) in sirolimus (bold black lines, n = 71) and cyclosporine groups (dashed lines, n = 74).

  • New classification of donation after circulatory death donors definitions and terminology
  • Vascularized composite allotransplantation: current standards and novel approaches to prevent acute rejection and chronic allograft deterioration
  • Dynamic changes of B‐cell compartments in kidney transplantation: lack of transitional B cells is associated with allograft rejection
  • Complement inhibition as potential new therapy for antibody-mediated rejection
  • Clinical consequences of circulating CD28-negative T cells for solid organ transplantation
  • Impact of de novo donor-specific anti-HLA antibodies on grafts outcomes in simultaneous pancreas–kidney transplantation
  • Eight-year results of the Spiesser study, a randomized trial comparing de novo sirolimus and cyclosporine in renal transplantation

Recently Published Issues

See all

  • Current Issue:August 2016

    Volume 29, Issue 8

  • July 2016

    Volume 29, Issue 7

    Special Issue: Focus Issue - Donation after Cardia...

  • June 2016

    Volume 29, Issue 6

    Special Issue: Focus Issue - Vascularized Composit...

  • May 2016

    Volume 29, Issue 5

  • April 2016

    Volume 29, Issue 4

Transplant International Focus Issue Collection

Focus Issue Collection

Video Highlights

Watch the Video!

2013 IF

Video interview with the winner of the rising star session of the ESOT Congress Brussels 2015, Karl Hillebrandt.

Video Interview


Dr. Pietro Cippà interviews the winner of the rising star session of the ESOT Congress Brussels 2015, Karl Hillebrandt. Karl presents his work on the topic of 'Optimized decellularization of rat livers byarterial and portal venous perfusion underoscillating pressure conditions'.

SEARCH

SEARCH BY CITATION